The most prescribed antibiotics were piperacillin/tazobactam (22), ceftriaxone (16), cotrimoxazole (15), amoxicillin/clavulanate (8) and metronidazole (5).The sources of infection were respiratory (26.2%), urinary (21.3%), intra-abdominal (21.3%), skin and soft tissue (9.8%), catheter-associated (6.6%) and unclear (14.8%).Recommendations were made to continue treatment (67.8%), discontinue for excessive duration (10.3%), de-escalate (9.2%), discontinue for unnecessary antimicrobial (8.0%) and escalate (4.6%).The acceptance rate was 98.8%. Conclusion and relevanceThe recommendations made by the ASP team were almost entirely accepted by the responsible clinician. Advice from a multidisciplinary team of experts in the field benefits these patients in optimising their antimicrobial therapy.
Aim and objectives The objective of this study was to describe the current status of clinical trials (CT) for AD in our hospital pharmacy service and to analyse the investigational drugs. Material and methods An observational descriptive retrospective study was carried out in a tertiary academic hospital. All active CT in the neuropsychology service from 1 January 2014 to 31 March 2019 were reviewed. Collected data were total number of CT; total number of included patients; demographic data; total number of CT classified by CT status (active/closed); clinical trial phase; therapeutic targets (reduction of amyloid plaques (AP)/precursor amyloid peptide (PAP) attack/inhibition of GLYT1 transporter/selective antagonism of 5-HT6 receptor/partial selective agonism of a 7 nicotinic receptor); administration route (oral/intravenous/subcutaneous); clinical trials with results; and type of result (positive/negative). Results Twelve CT were analysed involving a total of 59 patients (mean 5 patients per clinical trial (rank 0-8)), 34 (57.6%) women with a mean age of 77.4 years (95% CI 71.5-84.7). Six (50.0%) CT were active; 3 (25.0%) CT were phase II trials and 9 (75.0%) were phase III trials. Therapeutic targets were reduction in AP 5 (41.7%), attack of PAP 3 (25.0%), inhibition of GLYT1 transporter 1 (8.3%), selective antagonism of 5-HT6 receptor 2 (16.7%), partial selective agonism of a 7 nicotinic receptor 1 (8.3%); route of administration oral 7 (58.3%), intravenous 1 (8.3%) or subcutaneous 4 (33.3%); and 3 (25.0%) CT had results, all of which were negative (3 (100%)). Conclusion and relevance. The highest number of active CT were phase III trials.. Only 25% of CT had results and all were negative.. Almost 60% of CT studied oral administration, which was patients' preference.. There were a total of five therapeutic targets but more than 40% of the CT evaluated the reduction in APs.. Based on these results, we should rethink the research on Alzheimer's disease before continuing to develop clinical trials with the same therapeutic target.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.